•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Moderna Inc shares extended gains on Monday as investors focused on reports that the company is researching a hantavirus vaccine and advancing early-stage work in the area.
In recent trading, Moderna shares have risen more than 16% over the past five days, trading at about $55.
Moderna has drawn attention because of its ongoing early-stage work on a hantavirus vaccine within its broader infectious disease research pipeline.
Hantavirus has recently been in the headlines after three passengers on a cruise ship in the Atlantic died earlier this month from the disease.
Despite the recent momentum, the commercial opportunity tied to hantavirus is generally viewed as limited due to the disease’s relatively low incidence.
The virus is not spread between people in the same way as respiratory illnesses such as Covid-19. Infections are typically linked to exposure to infected rodents.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
